{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:41:25Z","timestamp":1769600485932,"version":"3.49.0"},"reference-count":8,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2014,8,11]],"date-time":"2014-08-11T00:00:00Z","timestamp":1407715200000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:p><jats:sc>l<\/jats:sc>\u2010asparaginase is an aminohydrolase that deprives leukemia cells of <jats:sc>l<\/jats:sc>\u2010asparagine required for protein synthesis. Although studies in patients with acute lymphoblastic leukemia have shown that the addition of <jats:sc>l<\/jats:sc>\u2010asparaginase improved the overall remission rate, life\u2010threatening acute pancreatitis has occurred in 0.5\u20134% of patients. We describe the first adult case report, to our knowledge, of the successful use of octreotide as a chemoprotectant for the prevention of recurrent pegylated asparaginase (<jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ASP<\/jats:styled-content>)\u2013induced pancreatitis in a 21\u2010year\u2010old man with Philadelphia chromosome\u2013negative acute lymphoblastic leukemia. After recurrent <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ASP<\/jats:styled-content> administration during induction chemotherapy, he developed necrotizing pancreatitis, confirmed by abdominal computed tomography, and further asparaginase therapy was withheld. Currently, there are no specific treatment recommendations for the management of asparaginase\u2010induced pancreatitis other than drug discontinuation. After disease relapse, a pediatric <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ASP<\/jats:styled-content>\u2013containing regimen was initiated, and PEG\u2010ASP therapy was resumed due to its potential clinical benefit. Octreotide 100\u00a0\u03bcg subcutaneously 3 times\/day, utilized as a chemoprotectant, was found to prevent pancreatitis recurrence. The patient completed therapy and was able to receive a bone marrow transplant without further complications from <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ASP<\/jats:styled-content> therapy. Based on this patient's experience, we believe it is reasonable to reincorporate <jats:styled-content style=\"fixed-case\">PEG<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">ASP<\/jats:styled-content> after an episode of pancreatitis with use of octreotide as a chemoprotectant; however, this conclusion will need to be substantiated in a randomized clinical trial with a larger group of patients.<\/jats:p>","DOI":"10.1002\/phar.1460","type":"journal-article","created":{"date-parts":[[2014,8,11]],"date-time":"2014-08-11T23:03:39Z","timestamp":1407798219000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Successful Use of Octreotide as a Chemoprotectant for Prevention of PEG\u2010Asparaginase\u2013Induced Pancreatitis"],"prefix":"10.1002","volume":"34","author":[{"given":"Larry W.","family":"Buie","sequence":"first","affiliation":[{"name":"Department of Pharmacy University of North Carolina Health Care Chapel Hill North Carolina"},{"name":"Eshelman School of Pharmacy University of North Carolina Chapel Hill North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of North Carolina Health Care Chapel Hill North Carolina"},{"name":"Eshelman School of Pharmacy University of North Carolina Chapel Hill North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hank","family":"van Deventer","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Department of Medicine University of North Carolina Health Care Chapel Hill North Carolina"},{"name":"Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,8,11]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.3109\/08880019809018315"},{"key":"e_1_2_5_3_1","first-page":"535","article-title":"l\u2010asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia","volume":"37","author":"Ortega JA","year":"1977","journal-title":"Cancer Res"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08971.x"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1211"},{"key":"e_1_2_5_6_1","unstructured":"HoelzerD.German multicenter trial for treatment of newly diagnosed acute lymphoblastic leukemia in adults (07\/2003). In: Clinical Trials.gov [Internet].Bethesda MD:National Library of Medicine (US)2003. Available fromhttp:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00198991NLM identifier: NCT00198991. Accessed April 29 2014."},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5856"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026679106463"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1249"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1460","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:23:35Z","timestamp":1761063815000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":8,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1002\/phar.1460"],"URL":"https:\/\/doi.org\/10.1002\/phar.1460","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"2014-08-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}